Conduit Pharmaceuticals Inc. (CDT)
- Previous Close
0.3966 - Open
0.4000 - Bid 0.2800 x 200
- Ask 0.5006 x 200
- Day's Range
0.3804 - 0.4000 - 52 Week Range
0.3700 - 328.0000 - Volume
407,818 - Avg. Volume
3,124,255 - Market Cap (intraday)
4.535M - Beta (5Y Monthly) 2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-20.5300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
www.conduitpharma.comRecent News: CDT
View MorePerformance Overview: CDT
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CDT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CDT
View MoreValuation Measures
Market Cap
4.54M
Enterprise Value
11.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-168.82%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.8M
Diluted EPS (ttm)
-20.5300
Balance Sheet and Cash Flow
Total Cash (mrq)
554k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.65M